Genmab
kr 2,343.00Change from previous close: +1.12%Absolute change: +kr 26.00
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- kr 144.34B
- Enterprise value
- kr 141.85B
- P/E (trailing 12 months)
- 27.7
- Forward P/E
- 21.2
- PEG
- 4.48
- Price/book
- 3.53
- Price/sales
- 34.9
- EV/EBITDA
- 103.0
- EV/revenue
- 34.3
Profitability and growth
- Gross margin
- 93.0%
- Operating margin
- 35.2%
- Net margin
- 19.1%
- ROE
- 14.0%
- ROA
- 8.8%
- Revenue growth (year over year)
- 24.9%
- Earnings growth (year over year)
- -9.4%
Financial health
- Total cash
- kr 1.51B
- Total debt
- kr 5.27B
- Debt/equity
- 0.89
- Current ratio
- 2.46
- Quick ratio
- 2.44
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- kr 2,453.79
- Median price target
- kr 2,500.00
- High price target
- kr 2,930.00
- Low price target
- kr 1,400.00
- Analysts with a price target
- 15
- Consensus
- Buy
- Forward EPS
- kr 108.97
- EPS estimate, current year
- kr 83.31
Shares and trading
- Beta
- 0.70
- Average volume
- 114.81K
- Shares outstanding
- 62.41M
- Float
- 58.96M
- Institutional ownership
- 42.4%
- Insider ownership
- 1.1%